For chronic lymphocytic leukemia, there is no clear evidence that disease-directed treatment has a life-prolonging effect. The treatment can, however contribute to extending remission and symptom-free periods. This means that treatment is initiated when the disease causes symptoms.
The most common indications for anti-leukemic treatment of chronic lymphatic leukemia:
- bone marrow failure equivalent to Binet's stage C
- general symptoms such as weight loss and night sweats
- large symptom-causing tumor
- troublesome lymph node tumor
- rapidly progressive lymphocytosis (lymphocyte doubling time < 6 months)
- autoimmune hemolytic anemia and/or immune-mediated thrombocytopenia, which does not respond to high doses of steroids or is recurring after reduction of treatment intensity.
- For the patient to be symptom-free as long as possible.
- To maintain good quality of life for the patient.
Norsk selskap for hematologi. Handlingsprogram for kronisk lymfatisk leukemi [Online] 2005 [hentet 15. april 2007]; tilgjengelig fra: URL: http://www.legeforeningen.no/index.gan?id=84611